← Research & Industry News
External source
STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies
Rare disease advocates applauded the FDA's move to speed access to treatments.
- Published by
- STAT
- Evidence type
- Regulatory
Rare disease advocates applauded the FDA's move to speed access to treatments.
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at STAT.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.